What is the importance of vasopressin in memory processes?

Social and individual recognition in rodents: Methodological aspects and neurobiological bases

What animals know about each other, and how they construct and use knowledge of their social world involves at least an ability to recognise different social categories. Although much evidence has accumulated that animals are able to identify and classify other individuals into different categories, few studies have definitively demonstrated true individual recognition, i.e. discrimination between individuals on the basis of their idiosyncratic characteristics. Furthermore, the neural structures and pathways involved in social and, a fortiori, individual recognition have as yet been poorly investigated. This paper discusses various methods and measures currently used to assess different forms of social categorisations in animals, with special reference to rodents. Recent progress concerning the neurobiological bases involved in social recognition is also discussed. Finally, integrative perspectives for studying individual recognition in the context of social cognition is underlined in relation to different approaches investigating rodents' ability to use learned olfactory information.

The effects of vasopressin on memory processes in Java monkeys

The roles of vasopressin (arginine-vasopressin) in controlling conditioned operant food-procuring reflexes and various types of memory were studied in monkeys. Types of memory were: conditioned reflex, image (Hunter-Kerr test), short-term, and long-term. The effects of vasopressin were assessed in terms of objective measures of higher nervous activity: movement and autonomous functions. These studies showed that administration of vasopressin to monkeys had different effects on simple operant food-procuring responses and memory processes. Vasopressin had greater effects on memory processes and the restoration of memory after functional derangements of higher nervous activity. The question of the formation of the two types of effect of vasopressin on higher nervous activity is discussed in relation to the evolution of mammals.

Decreased performance in a delayed alternation task by rats genetically deficient in vasopressin

Acquisition and retention of a delayed alternation task by rats genetically deficient in vasopressin (AVP) due to the homozygous occurrence of the Brattleboro diabetes insipidus (DI) gene (M520/DI) were compared to the response of rats that were heterozygous (M520/HZ) or normal (M520/N) with respect to the DI gene. No significant difference in the adaptation to the apparatus was observed between the groups. However, the rate at which the M520/DI rats acquired the alternation task was significantly slower than the acquisition rates of M520/HZ and M520/N rats. In addition, the maximum intertrial interval reached by the M520/DI rats was significantly shorter than the intertrial intervals reached by the M520/HZ and M520/N rats, indicating the ability to retain information was impaired in the M520/DI rats. These results are consistent with the hypothesis that AVP modulates the acquisition and retention of information for normal memory processes.

Behavioral effects of neurohypophyseal peptides in healthy volunteers: 10 years of research

A short summary of behavioral studies on the effects of vasopressin and oxytocin published during the past decade is provided. Only studies using healthy volunteers as subjects were included. Among the studies reviewed, large differences exist with respect to design, procedure, treatment schedule and dose used. Results from the majority of the studies support that vasopressin and oxytocin affect central nervous functions in man after systemic administration. Since the hormonal influences do not appear to be consistently restricted to certain stages of stimulus processing but nonspecifically concern a great variety of cognitive functions, it is suggested that the influence of hypophyseal peptides on stimulus processing is mediated through an action on basic mechanisms involved in the general regulation of central nervous activation, i.e., on arousal systems that could also alter affective aspects of stimulus processing. The altogether moderate number of studies, so far, does not provide a sufficient data base justifying a clinical application of these peptides as nootropic treatments.

Vasopressin and cognitive processes: two event-related potential studies

Two experiments studied the influence of arginine-vasopressin (AVP) on cognitive processes by means of an electrophysiological measure, the late positive complex (LPC) of the event-related potential. The LPC varies systematically with cognitive processes. The classical oddball paradigm and an incidental memory task (structural encoding of emotional adjectives) were used. The two studies differed only in the dose of AVP (study 1: three time nasal application of 10 IU AVP; study 2: 20 IU). In study 1, AVP intake enhanced memory performance. The LPC elicited by oddball stimuli was not influenced by AVP, neither when compared before and after intake nor when compared to placebo treatment. However, specific influences of AVP on the LPC elicited during the structural encoding task were observed. In both studies, AVP intake resulted in a marked change of the scalp distribution of the P3 component, which is a prominent part of the LPC. Furthermore, subjects treated with the lower dose of AVP showed a more positive P3 component on emotional (negative and positive) adjectives, when compared to neutral ones. The results suggest that vasopressin influences the central nervous processing of the emotional content of stimuli.

Effects of vasopressin on the habituation of the orienting reaction in men

Effects of arginine-vasopressin (AVP) on the habituation of the orienting reaction and response to stimulus mismatch were investigated in a between-group design with 40 healthy male volunteers using skin conductance and heart rate responses as dependent measures. Twenty-one 1000 Hz tones of 90 dB(A) intensity and 2 s duration were presented with alternating intervals of 20 and 140 s. Stimulus mismatch responses were analyzed to the tones after the long intervals and to a change of the interval duration. The expected prevention of habituation as an indicator of a general stimulus-related increase of phasic arousal under AVP could not be confirmed. There were no differences between the AVP and the placebo group in the skin conductance and heart rate responses. The interval change did not provoke a dishabituation reaction, but responses to the tones after the long intervals were reliably enhanced. However, AVP did not increase the reaction to stimulus mismatch. It is concluded that autonomic indicators of the habituation of the OR remain unaffected by AVP.

The enhancement of retention induced by vasopressin in mice may be mediated by an activation of central nicotinic cholinergic mechanisms

Immediate post-training subcutaneous administration of lysine vasopressin (LVP, 0.003-1.00 microgram/kg) enhanced retention, whereas the vasopressin antagonist AAVP (0.01-0.30 microgram/kg) impaired it, in male Swiss mice tested 48 h after training in an inhibitory avoidance task. Both effects were dose-dependent. Neither LVP nor AAVP affected response latencies in mice not given the footshock on the training trial. The simultaneous administration of AAVP at a dose (0.01 microgram/kg) which had no effect on retention shifted the dose-response curve of LVP to the right. Nicotine (1.0-30.0 micrograms/kg, sc), a central nicotinic cholinergic agonist, also facilitated retention in a dose-related manner without affecting the retention performance of unshocked mice. The effect of nicotine was prevented by the central acting nicotinic cholinergic receptor antagonist mecamylamine (5 mg/kg, sc.). In contrast, neither hexamethonium (5 mg/kg, sc), a peripheral acting nicotinic receptor blocker, nor atropine (0.5 mg/kg, sc) or methylatropine (0.5 mg/kg, sc), two anticholinergic drugs which are known to act on muscarinic cholinergic receptors, prevented the effect of post-training nicotine. The effects of LVP and nicotine were time-dependent, suggesting that both treatments enhanced retention by influencing post-training processes involved in memory storage. Low doses of nicotine (1.50 microgram/kg, sc) or the central anticholinesterase physostigmine (35 micrograms/kg, sc) and LVP (0.003 microgram/kg, sc), which had no effect on retention when administered alone, produced a synergistic interaction when given together following training. The influence of LVP (0.03 microgram/kg, sc) on retention was prevented not only by AAVP (0.01 microgram/kg, sc) but also by mecamylamine (5 mg/kg, sc), whereas the effects of nicotine (10.0 micrograms/kg, sc) were prevented only by mecamylamine. These results suggest that the enhancement of retention induced by vasopressin is probably due to an activation of central nicotinic cholinergic mechanisms which are critical for memory formation.

Lesions of parvocellular subdivisions of the hypothalamic paraventricular nucleus alter open field behavior and acquisition of sensory and spatial discrimination

Rats with ibotenic acid (IBO) lesions of the hypothalamic paraventricular nucleus (PVN) were compared with operated control animals over a battery of tests designed to assess memory- and arousal-related behavioral processes. At the dose employed in these experiments, ibotenic acid selectively destroys parvocellular elements of the PVN, leaving magnocellular subdivisions relatively intact, allowing for experimental dissection of the influence of parvocellular and magnocellular PVN neuronal populations on the behavioral parameters measured. IBO-treated rats showed a greater incidence of rearing behavior and exhibited greater levels of total and central ambulation in an open field than control rats. Acquisition of both the sensory and spatial reward contingencies were retarded in the IBO-lesion group; however, no differences were evident between IBO-treated and control groups in an approach-avoidance test, nor in the ability to perform the spatial and sensory discrimination tasks to a criterion level of accuracy. Histological examination verified that bilateral IBO lesions destroyed parvocellular elements of the PVN, while sparing the majority of magnocellular neurons. Results suggest that parvocellular PVN lesions alter behavioral performance via interactions with physiological systems governing arousal level.

Centrally administered vasopressin antagonizes pentobarbital-induced narcosis and depression of hippocampal cholinergic activity

Intracerebroventricular (ICV) microinjection of arginine vasopressin (AVP) to pentobarbital-anesthetized rats produced shortening of the duration of narcosis. This analeptic effect was blocked by atropine, indicating the central cholinergic nature of the response. AVP also increased hippocampal sodium-dependent high affinity choline uptake activity that had been depressed by the barbiturate. The AVP analeptic effect was blocked by pretreatment with a V-1 (vasopressor), but not a V-2 (antidiuretic), vasopressin receptor antagonist. These results suggest that ICV AVP produces its analeptic effect by interacting with central V-1 receptors to activate a hippocampal cholinergic arousal system. The cholinergic arousal effect may be a factor in the memory enhancing property of AVP.

A placebo-controlled evaluation of vasopressin for ECT-induced memory impairment

Vasopressin may be involved in normal memory functions and may alleviate certain memory impairments. In this study, the usefulness of vasopressin to relieve electroconvulsive therapy (ECT)-induced memory impairment was evaluated using a placebo-controlled, random assignment, double-blind design. Patients were 33 depressives receiving bilateral ECT. Vasopressin, in a nasal spray, was administered q.i.d. from the first through the fifth ECT. Extensive memory testing evaluated both retrograde and anterograde amnesia; ratings of depression and patient ratings of subjective memory complaints were also obtained. Results did not show statistically significant evidence of benefit from vasopressin, though a number of comparisons were in the predicted direction. The role of vasopressin in reducing memory impairment of various types remains to be elucidated.

Facilitation of inhibitory avoidance by hypertonic saline is reversed by a vasopressin and a nicotinic antagonist

Hypertonic saline (1 ml of 0.25, 0.50, and 1.00 M NaCl, ip) facilitated retention of a one-trial, step-through inhibitory avoidance task when injected into male Swiss mice 10 min after training, as indicated by retention performance 48 h later. A similar result was obtained after a subcutaneous injection of lysine vasopressin (LVP, 0.03 microgram/kg). Neither hypertonic saline nor LVP modified latencies to step-through of mice that had not received a footshock during training. The enhancement of retention produced both by hypertonic saline and by LVP was prevented by the vasopressin receptor antagonist AAVP (0.01 microgram/kg, sc) given after training, but 10 min before the treatments. The effect of hypertonic saline was also prevented by the central acting cholinergic nicotinic receptor antagonist mecamylamine (5 mg/kg, sc). On the contrary, neither hexamethonium (5 mg/kg, sc), a peripheral acting nicotinic receptor blocker, nor atropine (0.5 mg/kg, sc) or methylatropine (0.5 mg/kg, sc), two anticholinergic drugs which are known to act on cholinergic muscarinic receptors, prevented the effect of post-training hypertonic saline. These results suggest that a peripheral osmotic stimulus, probably through an endogenous release of vasopressin, may be behaviorally significant, and are consistent with the view that vasopressin may modulate the activity of central cholinergic nicotinic mechanisms which are critical for the behavioral change observed.

Effects of DGAVP on verbal memory

Effects of DGAVP (desglycinamide-arginine-vasopressin, a synthetic vasopressin analog) on verbal memory were investigated in 13 healthy male volunteers. Ten word lists, each consisting of 15 words, were presented to the subjects who had to recall them according to a free recall paradigm. The total number of recalled words was not different between DGAVP and placebo treatment; but DGAVP had an effect on memory performance depending on the serial position of the words. It attenuated the primacy effect and enhanced the recency effect of memory performance. The pattern of changes after DGAVP may be consistent with an effect of the peptide on general arousal. Since the experiment was not designed to test influences of DGAVP on arousal, these considerations remain tentative.

Can vasopressin alone act as an unconditioned stimulus to produce passive avoidance behaviour in rats in a typical memory experiment?

The claim that vasopressin improves memory has been largely based on results obtained from shock avoidance experiments. In the majority of these studies, "memory" was defined operationally as the hesitation of a rat to enter the darkened compartment of a box in which it had once received an electric foot-shock. A single post-trial injection of arginine vasopressin (AVP) enhances such passive avoidance behaviour. In view of the recent demonstration that AVP has aversive effects, it was argued that vasopressin alone (without giving the rats foot-shock, prior to the peptide) might be a sufficient inhibitory stimulus to produce passive avoidance behaviour in a typical memory experiment. This hypothesis was tested in the present study. The results of these experiments indicate that a behaviourally active dose of AVP (10 micrograms/kg; s.c.) was a sufficient stimulus to produce passive avoidance behaviour in the rats. A small dose of AVP (1.25 micrograms/kg; s.c.) was without effect. However, AVP (10 microgram/kg) was only effective with repeated administration (Experiment 1). This result is in contrast with the post-trial effect of the peptide on inhibitory avoidance behaviour, which is obtained with just one injection in the normal single trial step-through experiment. However, it was found that if the rats were injected with AVP (10 micrograms/kg) and placed in the dark compartment of the apparatus for 20 min, thereby ensuring that the animals made the explicit connection between the aversive effects of the peptide and the dark environment, they displayed avoidance behaviour after a single trial (Experiment 2).(ABSTRACT TRUNCATED AT 250 WORDS)

The role of arginine vasopressin in the development of tolerance to ethanol in normal and Brattleboro rats

Administration of AVP and related peptide fragments following ethanol (EtOH) administration has been shown to enhance retention of tolerance to ethanol. The present studies were designed specifically to: (1) examine the influence of AVP given concurrently with EtOH on the development of tolerance to the ataxic and hypothermic effects of EtOH in Long-Evans rats, and (2) to determine if tolerance to these effects develops in Brattleboro rats which are deficient in AVP. In Experiment 1, EtOH (2.5 g/kg, 15% v/v) was administered IP to 2 groups of rats in combination with a SC injection of either AVP (6 micrograms/kg) or an equal volume of saline. Two additional control groups received IP saline injections in combination with either saline or AVP. After 13 days, EtOH-treated rats were significantly more tolerant than saline-treated animals. AVP significantly increased the hypothermic and ataxic effects of EtOH and failed to enhance tolerance development. AVP delayed the extinction of tolerance to the hypothermic (but not the ataxic) effects of ethanol when administered during the extinction phase to rats previously treated with EtOH. In Experiment 2, Brattleboro rats were injected with EtOH or an equivalent volume of saline and tested for ataxia and hypothermia. Rats receiving EtOH failed to demonstrate significant tolerance to either effect of ethanol after 12 treatment days.

Vasopressin but not oxytocin enhances cortical arousal: an integrative hypothesis on behavioral effects of neurohypophyseal hormones

Behavioral changes after administration of the neurohypophyseal hormones vasopressin and oxytocin can be observed in animal and man. Several groups attempted to specify these changes in terms of memory or attention processing enhancement for vasopressin and amnesic properties for oxytocin. These interpretations, however, were targets for recent criticism. In a double-blind between-subject comparison with male volunteers receiving arginine-vasopressin (AVP), oxytocin or placebo intranasally prior to the experimental session, we tried to develop an alternative hypothesis on the basis of behavioral and EEG measures. At the beginning of the session subjects had to learn a list of 25 unrelated nouns within five trials. Recall was assessed 1 h later. Neither learning nor long-term recall were affected by peptide treatments. In a second vigilance task subjects had to covertly count eight series of tone pips. Averaged auditory evoked potentials to these tones showed the expected habituation during the course of the task within all three groups. Vasopressin-treated subjects, however, displayed significantly higher amplitudes of the vertex potential as compared to the other treatment groups. AVP effects were most prominent with the longest interstimulus interval. No influences on heart rate or blood pressure were found. Results indicate that vasopressin induces an enhancement of stimulus-related phasic cortical arousal, and that in this respect oxytocin has no effect.

Aversive conditioning of homozygous and heterozygous D.I. Brattleboro rats in the light-dark box

Active and passive avoidance, and conditioned freezing acquisition and retention were studied in HODI and HEDI Brattleboro rats. All animals were from the same source and of the same age and sex. The light-dark box test was employed. 0.6 and 2.0 mA footshocks were administered for the same number (7) of daily trials. Extinction time-course was followed for seven consecutive daily trials. Passive avoidance: the conditioned response was acquired and retained equally well by all Ss and for both shock intensities. Active avoidance: for 0.6 mA shocks HODI Ss acquired and retained the response significantly better than HEDI Ss; for 2.0 mA shocks the response was acquired equally by both groups of Ss, and retained significantly better by HODI Ss. Freezing: in general, HODI Ss exhibited less freezing then HEDI Ss. The diverse conditioned behavior of HODI and HEDI Ss in this paradigm, which allows the contemporaneous investigation of several aversive responses, does not support the hypothesis that vasopressin deficiency impairs learning and memory in the rat.

Behavioral effects of angiotensin II and angiotensin II-(4-8)-pentapeptide in rats

One nM of angiotensin II (AII) or angiotensin II-(4-8)-pentapeptide [AII(4-8)] given intracerebroventricularly did not affect locomotor and exploratory behavior of rats in open field. AII significantly increased and AII(4-8) did not affect vertical activity of animals in electromagnetic motimeter. Neither of the peptides influenced horizontal activity in the motimeter. Both peptides intensified stereotypy produced by apomorphine and amphetamine. AII significantly improved, while AII(4-8) did not affect, consolidation of memory of the correct way to food in T-maze. Similarly, AII increased and AII(4-8) did not change the rate of acquisition of conditioned avoidance responses in a shuttle-box. Of the two examined peptides only AII significantly improved retrieval of memory of the passive avoidance behavior. The results show that AII(4-8) influences central dopaminergic system but, unlike its parent peptide AII, has no apparent effect on memory.

Mecamylamine prevents the enhancement of retention induced by lysine vasopressin in mice

Lysine vasopressin (0.03 microgram/kg, sc) enhanced retention of a one-trial, step-through inhibitory avoidance task when injected into male Swiss mice immediately post-training, as indicated by retention performance 48 h later. A low dose of the vasopressin antagonist, AAVP (0.01 microgram/kg, sc), did not significantly affect retention, whereas a higher dose (0.03 microgram/kg, sc) impaired retention. Neither lysine vasopressin nor AAVP modified latencies to step-through of mice that had not received a footshock during training. The simultaneous injection of AAVP (0.01 microgram/kg, sc) prevented the enhancement of retention induced by lysine vasopressin. The influence of lysine vasopressin on retention was antagonized by the simultaneous administration of mecamylamine (5 mg/kg, sc) but not by hexamethonium (5 mg/kg, sc), atropine (0.5 mg/kg, sc), or methylatropine (0.5 mg/kg, sc). A modulatory role of vasopressin on the activity of central cholinergic nicotinic mechanisms which participate in memory formation is suggested.

Conditioned taste aversion in vasopressin-deficient rats (Brattleboro strain)

Brattleboro rats are homozygous for diabetes insipidus (DI), lacking the ability to synthesize vasopressin. Previous studies reported learning deficits in DI rats on passive avoidance tasks using footshock. Other studies, however, could not replicate these results. In two experiments, we studied the learning of DI and control Long Evans (LE) rats in a different avoidance paradigm: conditioned taste aversion (CTA). In the first experiment a mild CTA to saccharin was established gradually using low levels of an illness-inducing agent (lithium chloride). In the second experiment a strong CTA was established in one acquisition trial and the extinction of the conditioned aversion was followed for 12 trials. The two experiments found no differences between the DI and LE rats in either the magnitude or the rate of acquisition and extinction of the CTA. These results suggest that vasopressin is not involved in the acquisition and retention of CTA, and support previous studies indicating that vasopressin may not be involved in avoidance learning.

Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations

Vasopressin (AVP) and its analogues are reported to improve learning- and memory-related performance in experimental animals, and perhaps also in humans. Memory impairment is a clinical hallmark of the dementing disorder, Alzheimer's disease. We have examined AVP concentrations in postmortem brain tissue from 12 patients with histologically confirmed Alzheimer's disease and 13 control subjects. AVP was measured by a highly specific and sensitive radioimmunoassay, validated by parallel inhibition curves and high-performance liquid chromatography. Alzheimer brains had either normal or slightly increased AVP levels in the neocortex, which does not have AVP cell bodies. Significant reductions in AVP content were found in the hippocampus, nucleus accumbens, and globus pallidus interna. Levels were normal in all other regions studied. Abnormalities of the brain vasopressin system may contribute to the memory deficit associated with Alzheimer's disease.

Septal release of vasopressin in response to osmotic, hypovolemic and electrical stimulation in rats

The central release of vasopressin was studied in anesthetized rats using push-pull perfusions and radioimmunoassay of the hormone. A basal release was observed in the lateral septum and in the lateral ventricle, whereas no vasopressin was detected in the perfusates from the caudate nucleus. Under osmotic stimulation, vasopressin release increased up to 12 and 60 times basal levels following i.p. injections of 5 ml and 10 ml/kg b.wt. of 2 M NaCl, respectively. This increase was blocked by using a calcium-free perfusion medium containing 0.1 mM EGTA. In the lateral ventricle, osmotic stimulation (5 ml/kg of 2 M NaCl i.p.) had the same effect as in the septum. In the caudate nucleus, no release was observed. Hemorrhage also increased the septal release of vasopressin in 5 out of 6 animals tested. Electrical stimulation of the pituitary stalk and of the supraoptic nucleus was used to evoke the release of vasopressin into the bloodstream. Septal release slightly decreased during pituitary stalk stimulation, whereas it did increase during stimulation of the supraoptic region. Our results show that systemic stimuli for vasopressin release evoke both a peripheral and a septal release of the hormone. The dissociation of the effects of electrical stimulation of the pituitary stalk and of the supraoptic nucleus suggests, however, that the vasopressinergic neurones responsible for septal release are distinct from those which project to the neurohypophysis.

The use of avoidance training in studies of modulation of memory storage

Studies of the modulatory effects on memory of many treatments have relied in large part on the use of inhibitory (passive) avoidance training procedures. Recent critiques have questioned the validity of data obtained with the inhibitory avoidance task. This paper addresses these comments and describes many of the advantages of using the procedure in studies of processes which regulate the neurobiological mechanisms which store new information.

Vasopressin disrupts radial-maze performance in rats

The memory enhancing properties of vasopressin, observed in active and passive avoidance procedures, could derive from its influence on central systems, but may also be mediated by its endocrinological properties. Very little is known about the effects of vasopressin on behavior in procedures other than the active and passive avoidance paradigms. The present experiments were designed to assess the effects of vasopressin on behavior observed in the eight-arm radial maze. In Experiment I, male Wistar rats (N = 7), which had been extensively trained to collect food from all eight arms in a radial maze, were subcutaneously injected with different doses of vasopressin 5 min before the start of the session (0.00, 1.25, 3.75, and 6.25 micrograms/kg). In Experiment II, another group of male Wistar rats (N = 7) received the same doses of vasopressin after having been extensively trained to collect food from four of the eight arms. In both experiments, subjects spent more time in the maze as the dose of vasopressin was increased. Vasopressin also disrupted performance by preventing the subjects from visiting all of the baited arms in the maze. Performance thus decreased, not because of the fact that vasopressin interfered with memory processes, but because of the fact that it produced behavioral inhibition. Thus, if vasopressin affects memory processes, such effects are likely to be mediated through vasopressin's actions on endocrine and behavioral systems, rather than through a direct action on the neural substrate underlying memory functioning.

The effects of arginine-8 vasopressin on the cerebral cortex of rats anaesthetised with urethane

The effects of arginine-8 vasopressin (AVP) on the spontaneous electrical activity of the cerebral cortex were investigated in rats anaesthetised with urethane. Direct application of a relatively large concentration of AVP (0.5-2.0 mU AVP/microliter; 1.25-5.00 ng AVP/microliter) to the pial surface of a small area of the parietal cortex produced a complete cessation of spontaneous neural activity, which was often preceded by a short-lasting increase in frequency of discharge. There was also a decline in the number of large waves in the local electrocorticogram. These changes occurred after 1-4 min. A slow recovery began 10-30 min later, but was sometimes still incomplete after more than an hour. Only the first application of AVP produced the local effects described above. A second application, 2 hr later, was without effect. Direct application to a small area of one hemisphere did not alter the electrical activity of the contralateral cortex. Smaller concentrations of AVP (0.005-0.200 mU AVP/microliter; 12.5 pg-0.5 ng AVP/microliter) were variable in their actions. Occasionally, no effect at all was seen, while sometimes the cells stopped firing completely. However, the most usual consequence was a reduction in discharge frequency, the magnitude of which appeared to be related to the concentration of AVP applied. A second application of a small concentration of AVP usually failed to reduce the rate of spontaneous discharge.

Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats

The effect of intracerebroventricular (ICV) administration of cholecystokinin octapeptide (CCK-8) on electroconvulsive shock (ECS)-induced amnesia in passive avoidance response was studied in rats. In normal rats, CCK-8 in doses from 1 ng to 1 microgram had no effect on the response when injected before the training trials, immediately after foot shock or before the first retention test. However, proglumide, a CCK-8 receptor blocker, induced marked amnesia when injected in doses from 0.1 to 10 micrograms before the training trials and in doses of 1 and 10 micrograms before the first retention test, though not subsequent to foot shock. ECS given immediately after the foot shock caused amnesia in the 24 hr and 48 hr retention tests, which could have been prevented by CCK-8 injected in doses of 10 ng to 1 microgram prior to the training trials, of 10 ng to 1 microgram following ECS and of 0.1 and 1 microgram before the first retention test. In addition, the effects of CCK-8 and proglumide became pronounced following chronic ICV infusion, using an osmotic minipump, for 7 days at a dose of 1 ng/day and 10 ng/day, respectively. The amnesia induced by proglumide was not affected by arginine vasopressin (AVP), while AVP in doses of 10 ng and 100 ng given 30 min before the training trials prevented ECS-induced amnesia. The antiamnesic effect of AVP was abolished by simultaneous administration of proglumide. On the other hand, AVP-antiserum produced marked amnesia which could be antagonized by CCK-8. However, the antiamnesic effect of CCK-8 was not suppressed by AVP-antiserum.(ABSTRACT TRUNCATED AT 250 WORDS)

Peripheral injections of vasopressin control behavior by way of interoceptive signals for hypertension

The stimulus properties of peripheral injections of vasopressin were assessed using conditioned taste aversion techniques. Conditioned taste aversion induced by vasopressin was blocked by prior exposure to vasopressin but not to another aversive agent, apomorphine. Prior exposure to behaviorally equivalent doses of another hypertensive agent, angiotensin II, blocked also conditioned taste aversion induced by vasopressin and this effect was fully reciprocal, since prior exposure to AVP blocked the aversive effect of angiotensin II. The protection offered by prior exposure to angiotensin II was not due to an endogenous release of AVP since the aversive properties of angiotensin II were not blocked by administration of a specific antagonist of the vasopressor effects of vasopressin. These data suggest that the interoceptive cues which are responsible for the conditioned taste aversion induced by vasopressin are related to the hypertensive action of this peptide.

A mnemonic role for vasopressin: the evidence for and against

This review critically evaluates the animal and human research concerning vasopressin's putative mnemonic role. Weaknesses in the interpretations of the early animal experiments as well as the implications of the later inconsistent findings are discussed. It is concluded that both the initial enthusiasm and the subsequent skepticism concerning this hypothesized role were premature. This conclusion applies equally to the human research. A review of these studies reveals that almost all of the negative reports involved cognitively-impaired individuals. The relatively few studies that have been conducted concerning vasopressin's effects in unimpaired human subjects are consistent with the hypothesis that vasopressin does affect cognition, though both the mechanism of action and the specific cognitive processes which are altered have yet to be elucidated.

Aversive effects of subcutaneously injected vasopressin in the rat: independence of the ascending dorsal noradrenergic bundle

The unconditioned stimulus properties of subcutaneously administered arginine vasopressin (AVP) were examined using place and taste conditioning paradigms. Evidence for an aversive effect of the peptide was found, in general agreement with a previous report, although a high dose of AVP (10 micrograms) was required. Also investigated was the possible role of the dorsal noradrenergic bundle (DNAB) in conditioned taste aversion established by AVP. Although the DNAB has been proposed as one of the central pathways through which AVP exerts a facilitatory effect on conditioned behaviour, destruction of this pontine-forebrain projection with 6-hydroxydopamine did not appear to alter the aversiveness of the drug in the present study. These results replicate the finding that AVP can serve as an aversive stimulus but also indicate that the aversive properties of the peptide may prove to be dissociable from its ability to enhance the retention of learned behaviour.

Arginine vasopressin, stress, and memory

Arginine vasopressin (AVP) has been shown to have several non-renal actions including the potentiation of learned avoidance behavior in rats and improvement in cognitive functioning in humans. Research in our laboratory has confirmed these behavioral effects in rats using both peripheral and central injection of AVP. We have begun to examine the physiological basis for these effects. Peripheral administration of a vasopressor AVP antagonist reversed the prolongation of extinction produced by peripherally administered AVP in both active and passive avoidance, but also reversed the aversive unconditioned effects of AVP. However, central administration of the vasopressor AVP antagonist reversed peripheral effects of AVP only at doses shown to act peripherally to reverse vasopressor effects of AVP. An osmotic stress in doses known to liberate endogenous AVP mimicked the behavioral effects of exogenously administered AVP, and this stress effect was reversed by the AVP antagonist. These results support our hypothesis of separate but parallel AVP systems in the pituitary and brain with a role in behavioral adaptation to certain types of stress.

Effects of peripherally injected vasopressin and des-glycinamide vasopressin on the extinction of a spatial learning task in rats

An elevated eight-arm radial maze was employed to study the effects of neuropeptide administration on the spatial learning abilities of food-deprived rats. Following 18 days of reinforced training, each animal was briefly exposed to the maze with no food available in any of the eight food-cups. Immediately after this preliminary trial, animals were injected with a single subcutaneous dose of either saline, arginine vasopressin (AVP: 1.0 or 5.0 micrograms/kg), or an AVP analog with only weak endocrinological activity, des-gly-arginine vasopressin (DG-AVP: 1.0, 5.0 or 10.0 micrograms/kg). Additional extinction trials were conducted at 2, 4, 6 and 8 h post-injection. These tests consisted of individually placing an animal on the empty maze and recording the number of arms chosen in a 5-min period. In this situation, animals learn that food is no longer present in the maze and, consequently, extinguish responding. Vasopressin potentiated this radial maze extinction behavior while DG-AVP produced behavioral results directionally opposite to those predicted by a memory facilitation hypothesis. In a subsequent experiment, vasopressin had no effects on unconditioned locomotor activity measured 2 and 4 h post-injection. These results suggest that: vasopressin improved the learning that occurred during extinction of conditioned appetitive behaviors, these vasopressin effects on conditioned behavior were independent of any unconditioned, sedative or non-specific actions of the peptide, and peripheral endocrinological responses may be necessary to demonstrate memory-enhancing effects following peripherally administered AVP.

Vasopressin does not enhance memory processes: a study in human twins

Behavioral effects of lysin-vasopressin (LVP) were investigated applying two paradigms from human experimental psychology. The first task was designed to simulate amnesic symptoms in normals. The second task addressed the emotional value of the items to be processed. Additionally, EEG recordings were used as indicators of the central nervous system effectiveness of LVP. Blood pressure and heart rate measured peripheral arousal. The co-twin control method was employed to increase experimental power. Contrary to the prediction of the vasopressin memory hypothesis none of the specific memory parameters was improved by LVP treatment. Changes in the electrical activity of the brain, but not in blood pressure and heart rate indicated central nervous system actions of LVP. However, interpretation of LVP effects in terms of memory processing seems not to be justified.

Age effects on passive avoidance behavior of vasopressin-deficient Brattleboros

Experiments in which vasopressin-deficient Brattleboros were tested in a passive avoidance procedure have yielded contradictory results. Some investigators observed the passive avoidance behavior of these subjects to be inferior to that of normal controls, while others failed to observe such differences. Inspection of the literature suggested that age differences between subjects which participated in these experiments might be responsible for the discrepancy. In the present experiment, HO-DI and HE Brattleboro rats of different ages were tested in the standard passive avoidance task. Passive avoidance performance of HO-DIs was, indeed, influenced by the age of the subject at the time of testing; HO-DIs reentered the shock compartment sooner than HE at 35 days, but later than HE at 120 days. There was no difference between the two groups of subjects at 60 days. The percentage of HO-DIs which reentered the shock compartment on the post-shock trial decreased with increasing age.

Decreased high affinity 3H-imipramine binding in platelets of enuretic children and adolescents

High affinity 3H-imipramine binding sites have been demonstrated in human brain and platelet membranes. It has been suggested that these binding sites selectively label serotonin transporter or uptake sites. Since imipramine has a beneficial effect in the treatment of nocturnal enuresis, the present study was carried out to investigate a possible association between alteration in 3H-imipramine binding parameters in enuretics in comparison to nonenuretic control subjects. 3H-Imipramine binding to platelets was examined in 16 enuretic children and adolescents and compared to that in 22 healthy subjects of similar ages. A significant reduction was observed in the number of 3H-imipramine binding sites, while the dissociation constants (Kd) did not differ significantly in the platelets of enuretics as compared to controls. 3H-Imipramine binding values did not discriminate between familial and nonfamilial enuresis. These results may indicate that an alteration in the serotonin transporter in peripheral or central neuronal levels might be involved in the pathophysiology of nocturnal enuresis.

Influence on memory of posttraining or pre-test injections of ACTH, vasopressin, epinephrine, and beta-endorphin, and their interaction with naloxone

The intraperitoneal (i.p.) injection of ACTH 1-24 (0.2 microgram/kg), lysine--vasopressin (10.0 micrograms/kg) or epinephrine HCl (5.0 micrograms/kg) shortly after training or prior to testing caused memory facilitation of a step-down inhibitory avoidance task in rats, acquired with low intensity training footshocks (0.3 mA, 60 Hz). Naloxone HCl (0.4 mg/kg) potentiated their posttraining effect, but antagonized their pre-test effect. Naloxone on its own caused retrograde memory facilitation but had no effect on the test session. Posttraining human beta-endorphin (1.0 microgram/kg) was amnestic, and its pre-test administration enhanced retention. Both effects were naloxone-reversible. Neither the pre-test facilitation caused by beta-endorphin nor those caused by any of the other drugs (which are possible releasers of endogenous beta-endorphin) were observed in animals in which the influence of endogenous opioids was prevented at the posttraining period by the administration of naloxone. These results are compatible with, and considerably strengthen, the previously advanced hypothesis that learning of this task, and possibly others, depends on a state induced by beta-endorphin after training, and that it would normally be dissociated because this peptide is normally not released during test sessions. In addition, the posttraining facilitation caused by ACTH, vasopressin, and epinephrine stands out as an effect separate from, and in fact normally hindered by, posttraining beta-endorphin release.

Intracerebroventricular application of a vasopressin antagonist peptide prevents the behavioral actions of vasopressin

Three experiments were conducted to test the hypothesis that the memory-improving properties of peripherally-applied vasopressin (AVP) were related to its aversive (i.e. arousing) actions. The memory effects of AVP were observed in a one-trial food-finding task where non-deprived rats were briefly exposed to a large open field that contained an alcove in which a high-incentive familiar food reward (sweetened milk) was freely available. AVP injections immediately upon removal from the open-field produced faster latencies to refind the alcove (compared to vehicle controls) when tested 48 h later. The aversive actions of AVP were demonstrated in two behavioral assays: (1) a conditioned taste aversion test in which rats learned to avoid a preferred saccharin solution after it had been paired with injections of AVP; and (2) a conditioned place test in which rats learned to avoid a distinctive environment associated with AVP administration. Both the memory and aversive responses to AVP were prevented, in a dose-dependent manner, by immediate pretreatment with intracerebroventricular infusions of the pressor antagonist analog 1-deaminopenicillamine-2-(O-methyl)-tyrosine AVP. The large antagonist doses required to block AVP's behavioral effects suggest that the critical site of action may be far removed from the lateral ventricles. The possibility that AVP-induced improvements in memory result from peripheral arousing actions is discussed.

Choice, as opposed to latency, measures in avoidance suggest that vasopressin and oxytocin do not affect memory in rats

Latency measures from passive avoidance studies are frequently used as an index of memory. Thus, vasopressin (VP) is thought to enhance memory, since it has been shown to increase re-entry latencies. Conversely, several substances, such as oxytocin (OT), are supposed to have amnestic effects since they may decrease latencies. We describe a novel avoidance design, which allows latency to be assessed, but also permits the animal to re-enter into a distinctive compartment where shock had not been experienced (choice measure). Latency scores indicated that VP may improve memory, but the choice index suggested that this was not the case.

A procedure for small-volume brain grafting; vasopressin cells in neonatal and adult Brattleboro rats

A simple and reliable technique is described for the transplantation of fetal vasopressin (VP) neurons in the third ventricle of the brain of homozygous Brattleboro neonates. Small-volume grafting is introduced by microdissection of paraventricular and supraoptic areas and by pelleting the minced tissue for insertion into the transplantation cannula. Morphological and immunocytochemical evaluation yielded results in both neonatal and adult host brain that were similar to those described for anterior hypothalamic grafts in adult Brattleboro brain. The present protocol circumvents some of the general problems encountered when the use of small grafts is imperative, and is also applicable to the implantation of pelleted cell suspensions.